Prescription Drug Cardura Recalled for Specification Failures in Manufacturing
Viatris Inc is recalling Cardura (doxazosin mesylate) XL 8 mg tablets due to failed stability testing revealing out-of-specification impurity levels. Approximately 1,215 bottles distributed nationwide are affected.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II pharmaceutical recall for failed impurity specifications discovered during stability testing. Although no illnesses or adverse events have been reported, impurities in prescription medications represent a potential risk of harm warranting this classification.
Plain-English summary
Viatris Inc is recalling Cardura XL (doxazosin mesylate) 8 mg extended-release tablets in 30-count bottles. The recall affects Lot #8181625 with an expiration date of 12/31/2025 (NDC 58151-079-93).
The recall was initiated due to failed manufacturing specifications discovered during stability testing. Out-of-specification results were observed for impurity compound B, meaning the product did not meet the required quality standards for this component.
The affected product was distributed nationwide across the United States. Approximately 1,215 bottles of the 30-count product size are subject to this recall.
Patients with this medication should consult their pharmacist or healthcare provider with any questions about the recall.
The recalled product
- Product
- CARDURA (DOXAZOSIN MESYLATE)
- Brand
- CARDURA
- Manufacturer
- Viatris Inc
- Category
- Drug — Prescription Medication
- Hazard
- impurity
- degradation
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot # 8181625
- Exp 12/31/2025
UPCs (1)
- 0358151078936
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · CARDURA
- ModeratePrescription Drug Cardura XL Recalled for Out-of-Specification Impurity
FDA (Drugs) · 2025-01-22
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- SevereErythromycin Tablets Recalled for Impurity Above Acceptable Limits
FDA (Drugs) · 2026-05-27
- SevereAtomoxetine Capsules Recalled Due to Labeling Mix-Up Error
FDA (Drugs) · 2026-05-27
- ModeratePrimidone Tablets Recalled Due to API Cross-Contamination
FDA (Drugs) · 2026-05-27
- SevereCIMZIA injection recalled due to lack of sterility assurance
FDA (Drugs) · 2026-05-27